Pioneering Engineered
Antibody Immunotherapy

ISU ABXIS is pioneering the discovery of engineered antibody-based immunotherapy to target tumors and rare diseases. Our technology advances in antibody-based platform for the treatment of human disease.

ISU ABXIS NEWS

Get the latest ISU ABXIS’s press releases, announcements, and events.

  • 2022-01-26

    ISU ABXIS has signed a license agreement for “Fabagal” a therapeutic for Fabry disease, with NPO Petrovax Pharm located in Russia

     ISU ABXIS has signed a license agreement for “Fabagal”  a therapeutic for Fabry disease, with NPO

  • 2021-10-05

    ISU ABXIS to Present at Neuroscience 2021

    ISU ABXIS to Present at Neuroscience 2021 ISU ABXIS (KOSDAQ: 086890) announced the

  • 2021-10-01

    ISU ABXIS to Present Positive Phase 1 Data set on ISU104 Monotherapy or in Combination with Cetuximab in Patients with R/M HNSCC at ESMO Congress 2021

    ISU ABXIS to Present Positive Phase 1 Data set on ISU104  Monotherapy or in Combination with C

PIPELINE

ISU ABXIS is focused on the development of innovative antibody-based therapeutics that target significant unmet medical needs in oncology and rare diseases.

See our pipeline

ABOUT US

ISU ABXIS is dedicated to the development of novel antibody-based therapeutics that enhance the lives and ease the suffering of patients struggling with cancer and rare diseases.

Learn more about us